Citations

Clear

3 citation(s) found for "Spira, Avrum".

Precancer Atlas to Drive Precision Prevention Trials
Spira, Avrum, Yurgelun, Matthew B., Alexandrov, Ludmil, Rao, Anjana, Bejar, Rafael, Polyak, Kornelia, Giannakis, Marios, Shilatifard, Ali, Finn, Olivera J., Dhodapkar, Madhav, Kay, Neil E., Braggio, Esteban, Vilar, Eduardo, Mazzilli, Sarah A., Rebbeck, Timothy R., Garber, Judy E., Velculescu, Victor E., Disis, Mary L., Wallace, Douglas C., Lippman, Scott M., Braggio, Esteban , Velculescu, Victor E. , Alexandrov, Ludmil B. , Spira, Avrum, Yurgelun, Matthew B., Alexandrov, Ludmil, Rao, Anjana, Bejar, Rafael, Polyak, Kornelia, Giannakis, Marios, Shilatifard, Ali, Finn, Olivera J., Dhodapkar, Madhav, Kay, Neil E., Braggio, Esteban, Vilar, Eduardo, Mazzilli, Sarah A., Rebbeck, Timothy R., Garber, Judy E., Velculescu, Victor E., Disis, Mary L., Wallace, Douglas C., Lippman, Scott M., Braggio, Esteban , Alexandrov, Ludmil B

Mayo Clinic

Cancer Research | April 3, 2017 | Volume: 77 | Issue: 7 | Pages: 1510-1541

10.1158/0008-5472.can-16-2346 | PMID 28373404 Get It

Abstract Cancer development is a complex process driven by inherited and acquired molecular and cellular alterations. Prevention is the holy grail of cancer elimination, but making this a reality will take a fundamental rethinking and deep understanding of premalignant biology. In this Perspective, we propose a national concerted effort to create a Precancer Atlas (PCA), integrating multi-omics and immunity – basic tenets of the neoplastic process. The biology of neoplasia caused by germline mutations has led to paradigm-changing precision prevention efforts, including: tumor testing for mismatch repair (MMR) deficiency in Lynch syndrome establishing a new paradigm, combinatorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imaging-based early detection research in high-germline risk for pancreatic neoplasia, elucidating early ontogeny in BRCA1-mutation carriers leading to an international breast cancer prevention trial, and insights into the intricate germline-somatic-immunity interaction landscape. Emerging genetic and pharmacologic (metformin) disruption of mitochondrial (mt) respiration increased autophagy to prevent cancer in a Li-Fraumeni mouse model (biology reproduced in clinical pilot) and revealed profound influences of subtle changes in mt DNA background variation on obesity, aging, and cancer risk. The elaborate communication between the immune system and neoplasia includes an increasingly complex cellular microenvironment and dynamic interactions between host genetics, environmental factors, and microbes in shaping the immune response. Cancer vaccines are in early murine and clinical precancer studies, building on the recent successes of immunotherapy and HPV vaccine immune prevention. Molecular monitoring in Barrett's esophagus to avoid overdiagnosis/treatment highlights an important PCA theme. Next generation sequencing (NGS) discovered age-related clonal hematopoiesis of indeterminate potential (CHIP). Ultra-deep NGS reports over the past year have redefined the premalignant landscape remarkably identifying tiny clones in the blood of up to 95% of women in their 50s, suggesting that potentially premalignant clones are ubiquitous. Similar data from eyelid skin and peritoneal and uterine lavage fluid provide unprecedented opportunities to dissect the earliest phases of stem/progenitor clonal (and microenvironment) evolution/diversity with new single-cell and liquid biopsy technologies. Cancer mutational signatures reflect exogenous or endogenous processes imprinted over time in precursors. Accelerating the prevention of cancer will require a large-scale, longitudinal effort, leveraging diverse disciplines (from genetics, biochemistry, and immunology to mathematics, computational biology, and engineering), initiatives, technologies, and models in developing an integrated multi-omics and immunity PCA – an immense national resource to interrogate, target, and intercept events that drive oncogenesis. Cancer Res; 77(7); 1510–41. ©2017 AACR.
A Randomized Phase IIb Trial of myo -Inositol in Smokers with Bronchial Dysplasia
Lam, Stephen , Mandrekar, Sumithra J. , Gesthalter, Yaron , Ziegler, Katie L. Allen, Seisler, Drew K., Midthun, David E. , Mao, Jenny T., Aubry, Marie Christine, McWilliams, Annette , Shaipanich, Tawimas , Liu, Gang , Johnson, Evan, Bild, Andrea H. , Lenburg, Marc E. , Mayo, John R. , Yi, Joanne, Tazelaar, Henry D. , Harmsen, William S. , Smith, Judith, Beane, Jennifer , Szabó, Éva , Johnson, W. Evan , Allen Ziegler, Katie L, Yi, Joanne Eunhee, Tazelaar, Henry, Limburg, Paul J. , Sin, Don D , Johnson, Evan, Ionescu, Diana N. , Tazelaar, Henry D. , Spira, Avrum , Szabo, Eva

Mayo Clinic

Cancer Prevention Research | September 22, 2016 | Volume: 9 | Issue: 12 | Pages: 906-914

10.1158/1940-6207.capr-15-0254 | PMID 27658890 Get It

Abstract Previous preclinical studies and a phase I clinical trial suggested that myo-inositol may be a safe and effective lung cancer chemopreventive agent. We conducted a randomized, double blind, placebo-controlled phase IIb study to determine the chemopreventive effects of myo-inositol in smokers with bronchial dysplasia. Smokers with ≥1 site of dysplasia identified by autofluorescence bronchoscopy-directed biopsy were randomly assigned to receive oral placebo or myo-inositol, 9 g once a day for 2 weeks, and then twice a day for 6 months. The primary endpoint was change in dysplasia rate after 6 months of intervention on a per-participant basis. Other trial endpoints reported herein include Ki-67 labeling index, blood and bronchoalveolar lavage fluid (BAL) levels of proinflammatory, oxidant/antioxidant biomarkers, and an airway epithelial gene expression signature for PI3K activity. Seventy-four (n = 38 myo-inositol and n = 36 placebo) participants with a baseline and 6-month bronchoscopy were included in all efficacy analyses. The complete response and the progressive disease rates were 26.3% versus 13.9% and 47.4% versus 33.3%, respectively, in the myo-inositol and placebo arms (P = 0.76). Compared with placebo, myo-inositol intervention significantly reduced IL6 levels in BAL over 6 months (P = 0.03). Among those with a complete response in the myo-inositol arm, there was a significant decrease in a gene expression signature reflective of PI3K activation within the cytologically normal bronchial airway epithelium (P = 0.002). The heterogeneous response to myo-inositol suggests a targeted therapy approach based on molecular alterations is needed in future clinical trials to determine the efficacy of myo-inositol as a chemopreventive agent. Cancer Prev Res; 9(12); 906–14. ©2016 AACR.
Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
Kusko, Rebecca , Brothers, John F., Tedrow, John , Pandit, Kusum , Huleihel, Luai, Perdomo, Catalina, Liu, Gang , Juan-Guardela, Brenda, Zhang, Sherry , Lenburg, Marc E. , Quackenbush, John , Sciurba, Frank C. , Geraci, Mark W. , Yang, Ivana V. , Beane, Jennifer , Kaminski, Naftali , Limper, Andrew, Spira, Avrum , Kaminski, Naftali , Kass, Daniel J. , Martínez, Fernando J. , Limper, Andrew H. , Schwartz, David A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 22, 2016 | Volume: 194 | Issue: 8 | Pages: 948-960

10.1164/rccm.201510-2026oc | PMID 27104832 Get It

Abstract Rationale Despite shared environmental exposures, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease are usually studied in isolation, and the presence of shared molecular mechanisms is unknown. Objectives We applied an integrative genomic approach to identify convergent transcriptomic pathways in emphysema and IPF. Methods We defined the transcriptional repertoire of chronic obstructive pulmonary disease, IPF, or normal histology lungs using RNA-seq (n = 87). Measurements and Main Results Genes increased in both emphysema and IPF relative to control were enriched for the p53/hypoxia pathway, a finding confirmed in an independent cohort using both gene expression arrays and the nCounter Analysis System (n = 193). Immunohistochemistry confirmed overexpression of HIF1A, MDM2, and NFKBIB members of this pathway in tissues from patients with emphysema or IPF. Using reads aligned across splice junctions, we determined that alternative splicing of p53/hypoxia pathway–associated molecules NUMB and PDGFA occurred more frequently in IPF or emphysema compared with control and validated these findings by quantitative polymerase chain reaction and the nCounter Analysis System on an independent sample set (n = 193). Finally, by integrating parallel microRNA and mRNA-Seq data on the same samples, we identified MIR96 as a key novel regulatory hub in the p53/hypoxia gene-expression network and confirmed that modulation of MIR96 in vitro recapitulates the disease-associated gene-expression network. Conclusions Our results suggest convergent transcriptional regulatory hubs in diseases as varied phenotypically as chronic obstructive pulmonary disease and IPF and suggest that these hubs may represent shared key responses of the lung to environmental stresses.